Wellington Management Group LLP has sold 3,451 shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB).

2 min read | April 14, 2025 01:26 AM PDT | By Team Kalkine Media

Wellington Management Group LLP has sold 3,451 shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB). — Image source: Shutterstock

Market Movements and Performance Metrics

Y-mAbs Therapeutics opened trading at $4.83, marking an 11.0% increase. The company's shares have seen fluctuation with 50-day and 200-day moving averages standing at $5.18 and $8.75 respectively. The market capitalization is valued at $218.40 million, with a PE ratio of -8.94 and a beta of 0.71. Over the past year, the share price has ranged from a low of $3.86 to a high of $17.78, reflecting significant volatility.

Financial Performance and Revenue Insights

The company reported quarterly earnings with a loss of $0.15 per share, slightly deviating from analyst expectations. Revenue for the quarter totaled $26.50 million, just below the anticipated $26.70 million. Despite these results, the broader market sentiment remains cautiously optimistic regarding Y-mAbs Therapeutics' future performance.

Insider and Analyst Perspectives

Insider trading activity included a transaction by Thomas Gad, who sold 10,810 shares. Despite internal changes, corporate insiders maintain substantial ownership, accounting for 22.50% of the company. Analyst ratings reflect a spectrum of perspectives with varied price targets, notably Bank of America adjusting its price objective from $14.00 to $12.00, and Truist Financial updating its target to $18.00.

Company Profile and Product Portfolio

Y-mAbs Therapeutics, Inc. is a biopharmaceutical entity that focuses on antibody-based therapeutic products for cancer treatment, operating on a commercial stage. The company offers DANYELZA, a monoclonal antibody, for pediatric patients with specific cancerous conditions, indicating an emphasis on innovative treatment solutions.

Y-mAbs Therapeutics is navigating a dynamic market environment characterized by fluctuating investor interest and mixed analyst ratings. The company's strategic focus on antibody-based therapies presents potential long-term growth opportunities amidst the current institutional movements and market dynamics.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.